Whoops, we may have done it again: FDA wrong on naproxen CV risk?
This article was originally published in Scrip
Executive Summary
For the second time in recent months, US regulators are acknowledging they may have misjudged the severity of cardiovascular (CV) risks linked to a medicine – this time, naproxen.